The Food and Drug Administration has approved a new drug for people to take after they are exposed to COVID-19.
The FDA approved Xocova, a pill also known as ensitrelvir, on May 29, according to the FDA website. The approval is for post-exposure prophylaxis following COVID-19 exposure.
Labeling and other information have not yet been released.
Shionogi, the Japan-based company that makes Xovoca, said in a June 1 statement that the approval is for post-exposure prophylaxis in children and adults aged 12 years and older.
The treatment regimen is five days. Three tablets are taken on the first day. For the other four days, one tablet per day is taken….